The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Abstract
Background: Phosphoinositide 3-kinase (PI3Ks) is a member of intracellular lipid kinases and involved in the regulation of cellular proliferation, differentiation and survival. Overexpression of the PI3K/Akt/mTOR signalling has been reported in various forms of cancers, especially in colorectal cancers (CRC). Due to their significant roles in the initiation and progression events of colorectal cancer, they are recognized as a striking therapeutic target. Objective: The present review is aimed to provide a detailed outline on the role of PI3K/Akt/mTOR pathway in the initiation and progression events of colorectal cancers as well as its function in drug resistance. Further, the role of PI3K/Akt/mTOR inhibitors alone and in combination with other chemotherapeutic drugs, in alleviating colorectal cancer is also discussed. The review contains preclinical and clinical evidence as well as patent literature of the pathway inhibitors which are natural and synthetic in origin. Methods: The data were obtained from PubMed/Medline databases, Scopus and Google patent literature. Results: PI3K/Akt/mTOR signalling is an important event in colorectal carcinogenesis. In addition, it plays significant roles in acquiring drug resistance as well as metastatic initiation events of CRCs. Several small molecules of natural and synthetic origin have been found to be potent inhibitors of CRCs by effectively downregulating the pathway. Data from various clinical studies also support these pathway inhibitors and several among them are patented. Conclusion: Inhibitors of the PI3K/mTOR pathway have been successful for the treatment of primary and metastatic colorectal cancers, rendering the pathway as a promising clinical cancer therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Amerizadeh, F., Rezaei, N., Rahmani, F., Hassanian, S. M., Moradi‐Marjaneh, R., Fiuji, H., Boroumand, N., Tirkani, A. N., Ghayour‐Mobarhan, M., Ferns, G. A., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27367 · Cited by 97
RetractedLiu, W., Wang, S., Sun, Q., Yang, Z. H., Liu, M., & Tang, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.31232 · Cited by 83
RetractedThe phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
(2011) · Hepatogastroenterology · doi:10.5754/hge11453 · Cited by 1,254
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
Fumarola, C., Bonelli, M. A., Petronini, P. G., & Alfieri, R. R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.05.011 · Cited by 463
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
Mechanisms of drug resistance in colon cancer and its therapeutic strategies
Hu, T., Li, Z., Gao, C.-Y., & Cho, C. H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i30.6876 · Cited by 381
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
Cited by
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910260 · Cited by 402
Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44
Metadata
- Authors
- Narayanankutty, A.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2019-08-22
- Volume
- 20
- Issue
- 12
- Pages
- 1217-1226
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2951206054
- Cited by
- 255
- References
- 100
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence. https://app.cochat.ai/papers/10.2174/1389450120666190618123846
- The paper
- Narayanankutty, A. (2019). PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence. Current Drug Targets. https://doi.org/10.2174/1389450120666190618123846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.